Mainboard · BSE and NSEListed
Sai Parenteral’s Limited IPO: dates, price band, lot size, objects of the issue
Get analyst updates on this IPO
Analyst updates come by email.What changed since listing, from SEBI-registered research analysts.
By continuing you agree to the Terms and Privacy policy
Key facts
- Listing date
- Thu 2 Apr 2026
- BSE daily price file for Thu 2 Apr 2026
Timeline (IST)
- OpensTue 24 Mar 2026, 10:00 am IST confirmedRHP dated Mon 16 Mar 2026, page 2
- ClosesFri 27 Mar 2026 confirmedRHP dated Mon 16 Mar 2026, page 2
- UPI mandate cut-offNot stated in the RHP RHP dated Mon 16 Mar 2026
- AllotmentMon 30 Mar 2026 by T+3 schedule
- Refund and unblockWed 1 Apr 2026 by T+3 schedule
- Shares to dematWed 1 Apr 2026 by T+3 schedule
- ListingThu 2 Apr 2026 confirmedBSE daily price file for Thu 2 Apr 2026
Objects of the issue
| Object | Amount |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | ₹110.80 crore |
| Establishment of a new R&D Centre | ₹18.02 crore |
| Repayment / prepayment of certain outstanding borrowings | ₹14.30 crore |
| Working capital requirements | ₹33.00 crore |
| Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia) | ₹35.64 crore |
| General corporate purposes | Not stated in the RHP |
| Total | Not stated in the RHP |
The offer for sale goes to the selling shareholders, not the company. RHP dated Mon 16 Mar 2026, page 132
Company and promoters
As described in the RHP
Our Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. We are in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets.
RHP dated Mon 16 Mar 2026, page 29
Promoters
- 3 individual promoters
RHP dated Mon 16 Mar 2026, page 29
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 61.23% | Not stated in the RHP |
RHP dated Mon 16 Mar 2026, page 126
Financials (restated)
| Item | Six months period ended September 30, 2025 | Fiscal 2025 (March 31, 2025) | Fiscal 2024 (March 31, 2024) | Fiscal 2023 (March 31, 2023) |
|---|---|---|---|---|
| Revenue from operations | ₹86.92 crore | ₹163.11 crore | ₹153.76 crore | ₹96.80 crore |
| Profit after tax | ₹7.76 crore | ₹14.45 crore | ₹8.42 crore | ₹4.38 crore |
| Net worth | ₹209.37 crore | ₹95.78 crore | ₹76.40 crore | ₹31.49 crore |
| Total borrowings | Not stated in the RHP | Not stated in the RHP | Not stated in the RHP | Not stated in the RHP |
RHP dated Mon 16 Mar 2026, page 97
Who is selling in the offer for sale
| Selling shareholder | Type | Shares offered | Amount at the upper band |
|---|---|---|---|
| Vikasa India EIF I Fund | Fund | 4,30,000 | Not stated in the RHP |
| Individual shareholder | Individual | 2,22,222 | Not stated in the RHP |
| Individual shareholder | Individual | 2,22,218 | Not stated in the RHP |
| Individual shareholder | Individual | 2,22,000 | Not stated in the RHP |
| Individual shareholder | Individual | 2,22,000 | Not stated in the RHP |
| Individual shareholder | Individual | 2,00,000 | Not stated in the RHP |
| Individual shareholder | Individual | 2,00,000 | Not stated in the RHP |
| Individual shareholder | Individual | 1,80,000 | Not stated in the RHP |
| Individual shareholder | Individual | 1,40,000 | Not stated in the RHP |
| Individual shareholder | Individual | 1,40,000 | Not stated in the RHP |
| Total offer for sale | Not stated in the RHP | ||
RHP dated Mon 16 Mar 2026, page 1
Peer comparison (as in the RHP)
| Name of Company | Face Value Per Share (₹) | Closing price on February 03, 2026 (₹) | Revenue from Operations for Fiscal 2025 (₹ million) | EPS (₹) Basic | EPS (₹) Diluted | P/E (Times) | EV/EBITDA (Times) | MCap / Sales (Times) | Return on tangible Net Worth (%) | Net Asset Value per Equity Share (₹) |
|---|---|---|---|---|---|---|---|---|---|---|
| Company | 5 | [●] | 1,631.06 | 5.43 | 5.43 | [●] | [●] | [●] | 15.09 | 35.98 |
| Sai Life Sciences Limited | 1.00 | 879.15 | 16,945.70 | 8.83 | 8.61 | 107.70 | 40.66 | 10.81 | 7.99 | 102.12 |
| Innova Captab Limited | 10.00 | 727.20 | 12,436.76 | 22.41 | 22.41 | 32.45 | 22.35 | 3.35 | 13.37 | 167.66 |
| Senores Pharmaceuticals Limited | 10.00 | 817.65 | 3,982.50 | 16.12 | 16.12 | 64.30 | 33.82 | 9.46 | 7.18 | 176.37 |
| Gland Pharma Limited | 1.00 | 1,895.70 | 56,165.04 | 42.40 | 42.40 | 44.71 | 19.52 | 5.56 | 7.63 | 555.41 |
| Industry Average | 62.29 | 29.09 | 7.29 |
Reproduced from the RHP dated Mon 16 Mar 2026, page 170; InsightPier adds no figures
Risk factors
93 total- All manufacturing plants are in Hyderabad and Ongole, so local disruptions could hurt the business (RHP page 42)
- A large share of revenue comes from injectables, so lower demand for them could hurt results (RHP page 43)
- Plants face regulator and customer inspections that could lead to regulatory action (RHP page 44)
- No long-term supply contracts for raw materials; supply cuts or price swings could hurt results (RHP page 45)
- A few customers account for a large part of revenue; losing them could hurt the business (RHP page 47)
Offer document
Allotment and bids
Registrar to the issue: Bigshare Services Private Limited.
Allotment status was expected on the registrar's site from Mon 30 Mar 2026 and is not yet confirmed. Pick "Sai Parenteral’s Limited" from the issue list there.